SRR2016954
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.470
- ALLOGRAFT_REJECTION+0.410
- INTERFERON_GAMMA_RESPONSE+0.410
- COMPLEMENT+0.230
- INFLAMMATORY_RESPONSE+0.190
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.170
- IL6_JAK_STAT3_SIGNALING+0.160
- KRAS_SIGNALING_DN+0.160
- MYC_TARGETS_V2+0.140
- PANCREAS_BETA_CELLS+0.120
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.420
- NOTCH_SIGNALING-0.420
- HEDGEHOG_SIGNALING-0.410
- E2F_TARGETS-0.400
- TGF_BETA_SIGNALING-0.400
- G2M_CHECKPOINT-0.350
- WNT_BETA_CATENIN_SIGNALING-0.350
- CHOLESTEROL_HOMEOSTASIS-0.340
- PROTEIN_SECRETION-0.340
- UV_RESPONSE_DN-0.340
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-LL-A5YN-01A-11R-A28M-07 | — | B | 0.863 |
| 2 | SJEPD027_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.849 |
| 3 | KASUMI6_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.846 |
| 4 | TCGA-64-5778-01A-01R-1628-07 | — | cohortA1 | 0.824 |
| 5 | TCGA-62-A472-01A-11R-A24H-07 | — | cohortA1 | 0.816 |
| 6 | TCGA-CV-A461-01A-41R-A266-07 | — | — | 0.805 |
| 7 | s0122145 | — | — | 0.804 |
| 8 | b03d2223-38c1-4bb3-be8b-27db05f87b66 | — | — | 0.803 |
| 9 | e5c23a09-dd5f-4eda-8eca-f4aea9b71c20 | — | — | 0.803 |
| 10 | TCGA-WT-AB41-01A-11R-A41B-07 | — | B | 0.802 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.470 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.410 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.410 | Idelalisib | — uncovered |
| COMPLEMENT | 0.230 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.190 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.170 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.160 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.160 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.140 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.120 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.060 | Inavolisib | — uncovered |
| PEROXISOME | 0.040 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.030 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.010 | Idelalisib | — uncovered |